선택적 제품 분석
허용하는 경우 개인정보 보호를 고려한 제한적 분석을 사용해 어떤 리서치 여정이 효과적인지 파악합니다. 광고 추적기나 세션 녹화는 사용하지 않습니다. 환경설정에서 이 선택을 변경할 수 있습니다. 자세한 내용은 개인정보 처리방침.
Accelerating scaling of the global high-tech platform toward $4 billion in revenue by 2030 at a 25% operating income margin, powered by rapid adoption of CoolIT liquid cooling solutions in AI datacenters and debottlenecked bioprocessing purification capacity in China.
Water Services annual revenue growth decelerating below 2.0% YoY.
Ecolab Inc. While the company commands a Wide economic moat driven by high switching costs in Water Services and over 800,000 connected IoT sensors, the equity trades at 29.67x forward earnings —an unsustainable valuation premium that leaves investors completely unprotected against industrial demand deceleration or persistent commodity inflation.45
Ecolab is a premier specialty service and technology business with enduring competitive advantages. In FY2025, consolidated revenue reached $16,081.2M and operating income reached $2,737.6M (17.02% EBIT margin). The company generated $2,952.6M in and $1,904.3M in after funding $1,048.3M in . Water Services generated $7,679.9M (47.8% of revenue), and Global Institutional contributed $5,962.0M, forming a highly defensive consumable base.
Despite these outstanding structural qualities, current market pricing has decoupled from fundamental earnings power. At $273.70 per share, Ecolab trades at 29.67x NTM earnings. This stands at a 10.4-multiple premium over industrial gas peer APD (19.23x forward P/E) and significantly above Linde at 24.51x and Sherwin-Williams at 23.54x. In present-value terms, our fundamental fair value midpoint of $203.99 sits 31.6% below the present-value equivalent of the 12-month analyst consensus target ($298.06 PV, derived from undiscounted target $324.95 at Ke 9.0231%).34
Our multi-model valuation framework balances forward earnings power ($214.84 midpoint) and 10-year moat fade economics ($224.69 midpoint) against enterprise cash flow models that incorporate Ecolab's $8,783.1M net debt ($139.15 DCF midpoint). Even under an aggressive Bull scenario where high-tech liquid cooling accelerates toward $4B by 2030, equity value reaches only $251.65—still 8.06% below the October 2, 2026 price of $273.70. With risk-reward heavily tilted to the downside (-25.47% implied return), we recommend selling into strength.45
Water Services represents 47.8% of revenue ($7,679.9M in FY2025), delivering essential water purification and cooling tower treatments that customers cannot easily cancel or defer.8
Proprietary formulations and over 800,000 connected IoT devices allow Ecolab to pass through cost inflation within three months, defending gross margins far faster than peers.5
Integration of CoolIT expands data center addressable opportunity by 3x to 5x, while the newly commissioned China purification plant eliminates volume bottlenecks to drive double-digit growth toward a 30% ROI target.5
Sell. Ecolab is an outstanding wide-moat compounder whose equity valuation has become severely extended at 29.67x forward P/E, trading 34.17% above fundamental fair value of $203.99. Investors should trim into current strength to harvest gains.4
The majority of its Pest Elimination revenue is from services and is recognized when the services are provided, which is over time. Through this strategy and the breadth of its product and service mix, one customer may utilize the offerings of several of its operating segments. Important in its value proposition for customers is its ability to produce improved results while reducing their water and energy use. Its manufacturing facilities produce chemical products and equipment for all its operating segments, although Pest Elimination purchases the majority of their products and equipment from outside suppliers. Its chemical production process consists of blending purchased raw materials into finished products in powder, liquid, and solid form.
Additionally, intermediates from reaction chemistries are used in some of the blends and are also packaged directly into finished goods.
Under an adverse combination of cyclical manufacturing contraction, persistent high-single-digit raw material inflation, and debt refinancing pressures across Ecolab's $9,429.3M total debt obligation, consolidated operating margin would fall below 16.5% and revenue growth would stall below 2.0%. In this environment, free cash flow generation from the FY2025 baseline of $1,904.3M would be impaired while the market's elevated forward P/E of 29.67x de-rates toward peer medians (19.2x to 21.4x), confirming substantial downside toward the lower fair value boundary of $156.25.
A global industrial manufacturing downturn contracts Water Services demand, persistent commodity input cost inflation overwhelms customer pricing acceptance, and multiple de-rating toward peer medians drives fair value down to the lower boundary of $156.25.
Water Services delivered $7,679.9M in FY2025, accounting for 47.8% of consolidated sales ($16,081.2M). If global heavy industry and manufacturing utilization undergo a sustained contraction, industrial water consumption slows markedly, depressing segment revenue growth below 2.0% YoY and driving an estimated -28.5% fair value impairment.78
투자 논리를 약화시킬 수 있는 다섯 가지 변화입니다.
Industrial production deceleration causing manufacturing utilization cutbacks, depressing core water treatment consumable volume demand.
현재:$7,679.9M in FY2025 (47.8% of revenue)
다음이면 경고Water Services annual revenue growth below 3.0% YoY
Ecolab commands a wide economic moat rooted in high switching costs and proprietary chemistry that differentiates its business model from standard industrial chemical manufacturers. Rather than competing as an unbundled bulk chemical distributor, Ecolab couples customized chemical treatments with proprietary automated feed equipment and continuous digital monitoring systems, including AquaIQ, DishIQ, and 3D TRASAR. With more than 800,000 deployed IoT devices scaling past 1,000,000, the company's hardware and telemetry are deeply integrated into customers' primary water cooling, heating, and hygiene infrastructures.
The mission-critical nature of Ecolab's solutions creates powerful operational lock-in. Water treatment and infection prevention represent an immaterial fraction of a manufacturing facility's or hospital's total operational budget, yet chemical imbalances or microbiological contamination can trigger catastrophic facility shutdowns, regulatory penalties, or equipment corrosion. Consequently, enterprise clients face prohibitive friction and operational risk when contemplating a vendor switch. This entrenchment is reflected in Ecolab's ability to implement value pricing that offsets input cost inflation rapidly, compressing what used to be a two-year recovery cycle into a single quarter.
Furthermore, the company's debottlenecked purification manufacturing facility in China eliminates prior capacity limitations, opening a high-return growth vector in bioprocessing and pharmaceutical filtration targeted toward a 30% ROI. These structural moats allow Ecolab to generate an ROIC of 13.84%, comfortably exceeding its computed WACC of 8.3627%. However, this wide economic moat does not insulate public equity holders from valuation multiple overextension at the October 2, 2026 price of $273.70.
Ecolab generates an ROIC of 13.84% (with historical levels at 11.61%), comfortably exceeding its computed WACC of 8.3627%. This spread of approximately 5.48 percentage points demonstrates verified economic profit generation, supported by a 44.51% gross margin ($7,158.1M on $16,081.2M revenue) in FY2025.247
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
The highlighted cell is Fair value when every assumption sits at its base level ($203.99). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $2.1B after modeled reinvestment of $527.3M, with terminal value at 78.1% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Ecolab executes cleanly on its core operational targets: Water Services preserves steady consumable pricing and volume replenishment, operating margins expand toward guided targets, and China debottlenecking supports steady bioprocessing demand. However, even under this successful operating performance, fundamental cash flows yield Fair value of $203.99, indicating that shares at $273.70 reflect an implied return of -25.5%.458
A revenue and EPS beat validates pricing resilience, but given that shares trade at $273.70 against Fair value of $203.99, fundamental cash flows remain insufficient to warrant an aggressive change in stance.
Inline results confirm baseline earnings expectations but leave shares at $273.70 at a substantial premium over Fair value of $203.99, maintaining an implied return of -25.5%.
An earnings or margin miss exposes the vulnerability of trading at a forward P/E of 29.67x, increasing the likelihood of multiple compression toward peer medians.
Ecolab demonstrates high operating earnings quality anchored by robust cash conversion. In FY2025, operating cash flow reached $2,952.6M, comfortably exceeding GAAP net income of $2,075.6M and converting 107.8% of operating income ($2,737.6M). Stock-based compensation expense was $136.6M, representing an immaterial 0.85% of revenue ($16,081.2M). However, reported gross margins continue to reflect integration dilution, including a 60 bps drag from Ovivo.5
Reaching 20% operating margin by 2027 is the central operating assumption underpinning current earnings growth expectations.5
Cash flow conversion is robust. For FY2025, operating cash flow reached $2,952.6M and free cash flow stood at $1,904.3M after deducting $1,048.3M in capex. FCF converted 69.56% of operating income ($2,737.6M) and 91.75% of GAAP net income ($2,075.6M). High cash conversion is sustained by the consumable nature of water treatment chemicals and hygiene products. Working capital demands remain manageable, but commodity inflation could temporarily dampen conversion if inventory carrying costs rise.
ROIC is projected to expand organically by at least 100 basis points annually according to management, overcoming short-term denominator expansion caused by the CoolIT acquisition to return to pre-acquisition levels by 2028. The commissioning of debottlenecked purification manufacturing in China provides high-margin capacity targeting a 30% ROI, which will support structurally higher returns on capital over the next five years.
Ecolab's ROIC of 13.84% exceeds its computed WACC of 8.3627% by 5.48 percentage points, confirming substantial economic value creation across its core operating divisions.
FY2025 free cash flow reached $1,904.3M on operating cash flow of $2,952.6M and net income of $2,075.6M.
| 매출 | US$4,415,400,000 |
|---|---|
| 매출원가 | US$2,469,500,000 |
| 매출총이익 | US$1,945,900,000 |
| 영업비용 | US$1,188,000,000 |
| 영업이익 | US$757,900,000 |
| 영업외 항목 및 세금 | -US$223,000,000 |
| 순이익 | US$534,900,000 |
| 총자산 | US$24,696,300,000 |
|---|---|
| 현금 | US$646,200,000 |
| 유동자산 | US$5,955,600,000 |
| 총부채 | US$14,891,800,000 |
| 유동부채 | US$5,534,700,000 |
| 주주자본 | US$9,804,500,000 |
| 순이익 | US$2,075,600,000 |
|---|---|
| 영업 현금 유입 | US$2,952,600,000 |
| 감가상각비 | US$672,600,000 |
| 주식 기반 보상 | US$136,600,000 |
| 기타 영업 조정 | US$67,800,000 |
| 영업 현금흐름 | US$2,952,600,000 |
| 사용 가능 현금 | US$4,209,400,000 |
| 기초 현금 | US$1,256,800,000 |
| 투자 현금 유출 | US$2,707,200,000 |
| 자본적 지출 | US$1,048,300,000 |
| 기타 투자 활동 | US$1,658,900,000 |
| 재무 현금 유출 | US$853,300,000 |
| 환율 효과 | US$2,700,000 |
| 기말 현금 | US$646,200,000 |
| 투자 현금흐름 | -US$2,707,200,000 |
| 재무 현금흐름 | -US$853,300,000 |
| 사업 범주별 매출 | 매출 | 비중 | 전년 대비 |
|---|---|---|---|
| Cost of | 24.7억 | 55.9% | — |
| Other | 19.5억 | 44.1% | — |
2026-10-03 분석에 사용된 시점 재무 데이터입니다.
| 기간 | 매출 | EBITDA | 순이익 | 영업 현금흐름 | 잉여 현금흐름 | 자본적 지출 | 감가상각비 | 주식 기반 보상 | 자사주 매입 | 지급 배당금 | 순부채 발행 | 투자 현금흐름 | 재무 현금흐름 | 기초 현금 | 기말 현금 | 현금 및 투자자산 | 총부채 | 영업이익률 | ROIC | WACC | ROIC−WACC 스프레드 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | US$131.5억 | US$27.8억 | US$12.3억 | US$19.4억 | US$11.8억 | US$7.6억 | US$8.5억 | US$8570만 | US$7.4억 | US$4.3억 | — | -US$7.7억 | -US$8.7억 | — | US$3.8억 | US$3.7억 | US$66.9억 | 14.2% | — | 5.6% | — |
| 2017-12-31 | US$138.4억 | US$29.2억 | US$15억 | US$20.9억 | US$12.2억 | US$8.7억 | US$8.9억 | US$9050만 | US$6억 | US$4.5억 | — | -US$17.3억 | -US$5.2억 | US$3.8억 | US$1.6억 | US$2.4억 | US$73.2억 | 14.1% | — | 5.8% | — |
| 2018-12-31 | US$122.2억 | US$30.2억 | US$14.3억 | US$22.8억 | US$15억 | US$7.8억 | US$9.4억 | US$8800만 | US$5.6억 | US$4.9억 | — | -US$10.3억 | -US$11.7억 | US$1.6억 | US$2.4억 | US$1.6억 | US$70.5억 | 14.1% | — | 5.8% | — |
| 2019-12-31 | US$125.6억 | US$27.5억 | US$15.6억 | US$24.2억 | US$16.9억 | US$7.3억 | US$7.8억 | US$8400만 | US$3.5억 | US$5.5억 | — | -US$12억 | -US$13.5억 | US$2.4억 | US$1.2억 | US$1.2억 | US$68.2억 | 14.7% | — | 5.2% | — |
| 2020-12-31 | US$117.9억 | US$22.2억 | -US$12.1억 | US$18.6억 | US$13.7억 | US$4.9억 | US$8.1억 | US$8210만 | US$1.5억 | US$5.6억 | — | -US$4.1억 | -US$3.4억 | US$1.2억 | US$12.6억 | US$12.6억 | US$71.1억 | 11.8% | — | 4.7% | — |
| 2021-12-31 | US$127.3억 | US$24.7억 | US$11.3억 | US$20.6억 | US$14.2억 | US$6.4억 | US$8.4억 | US$8950만 | US$1.1억 | US$5.7억 | — | -US$45.8억 | US$16억 | US$12.6억 | US$3.6억 | US$3.6억 | US$91.6억 | 12.6% | — | 5.1% | — |
| 2022-12-31 | US$141.9억 | US$25.5억 | US$10.9억 | US$17.9억 | US$10.8억 | US$7.1억 | US$9.4억 | US$8780만 | US$5.2억 | US$6억 | US$8970만 | -US$7.2억 | -US$8.4억 | US$3.6억 | US$6억 | US$6억 | US$90.3억 | 11.0% | — | 7.3% | — |
| 2023-12-31 | US$153.2억 | US$30.3억 | US$13.7억 | US$24.1억 | US$16.4억 | US$7.7억 | US$9.2억 | US$9510만 | US$1370만 | US$6.2억 | -US$5억 | -US$9.9억 | -US$10.5억 | US$6억 | US$9.2억 | US$9.2억 | US$87.3억 | 13.0% | — | 7.6% | — |
| 2024-12-31 | US$157.4억 | US$38.5억 | US$21.1억 | US$28.1억 | US$18.2억 | US$9.9억 | US$9.4억 | US$1.3억 | US$9.9억 | US$6.6억 | -US$6.3억 | -US$4.3억 | -US$20.2억 | US$9.2억 | US$12.6억 | US$12.6억 | US$82.8억 | 17.8% | — | 8.4% | — |
| 2025-12-31 | US$160.8억 | US$34.6억 | US$20.8억 | US$29.5억 | US$19억 | US$10.5억 | US$6.7억 | US$1.4억 | US$7.8억 | US$7.5억 | US$4.7억 | -US$27.1억 | -US$8.5억 | US$12.6억 | US$6.5억 | US$6.5억 | US$94.3억 | 17.0% | — | 7.6% | — |
Ecolab Inc. (ECL) trades at 29.7x forward earnings against a peer median of 21.4x. Its EV/EBITDA of 20.7x compares with a peer median of 17.7x. The comparison uses 4 peers: The Sherwin-Williams Company, Air Products and Chemicals Inc., Linde plc and Freeport-McMoRan Inc., as of 2026-10-03.
Across the specialty chemical and basic materials benchmark, industry capex-to-revenue stands at 4.10% and industry capex-to-depreciation is 1.55x. Ecolab invested $1,048.3M in capex during FY2025 on $16,081.2M revenue (6.52% capex/revenue) against D&A of $672.6M (1.56x capex/depreciation).7
In an industrial upcycle, manufacturing capacity utilization expands, semiconductor fabrication plants scale, and AI data centers proliferate, driving surging demand for ultrapure process water and liquid cooling distribution units (CDUs). Ecolab leverages pricing power and operating leverage to expand margins toward 20%, while high-tech revenues scale toward their $4B 2030 target.
In a downcycle or manufacturing recession, industrial facility utilization contracts, diminishing demand for boiler, cooling, and wastewater process chemicals. When clients cut operating budgets, value pricing pushbacks intensify, squeezing Ecolab's operating margin from its FY2025 level of 17.02% and triggering equity de-rating toward mature chemical peer multiples.
Ecolab holds the leading global market position in commercial water treatment and institutional hygiene. Compared to capital-intensive industrial gas peers such as Air Products & Chemicals (operating margin 25.54%, forward P/E 19.23x) and Linde plc (operating margin 28.12%, forward P/E 24.51x), Ecolab operates a higher-turnover, consumable-focused service model. Its embedded service personnel and digital telemetry create stickier customer relationships, though current equity pricing at 29.67x forward P/E leaves no margin for cyclical underperformance.34
Ecolab shares trade at $273.70, representing a 34.17% premium to our synthesized intrinsic fair value of $203.99 and delivering an implied return of -25.47%. The stock trades at 29.67x forward P/E, well above mature peer medians (19.2x to 21.4x). Under our house Sell rating, recommended portfolio exposure is 0%.34
Risk management dictates strict avoidance of long exposure and systematic portfolio trimming under the current Sell recommendation. While Ecolab possesses high business quality and a wide economic moat, paying 29.67x forward P/E for a business carrying $9,429.3M in debt and facing high-single-digit input cost inflation exposes capital to severe downside asymmetric risk. Trim positions into any liquidity rallies and redeploy capital into assets offering positive margin-of-safety spreads.
Ecolab trades at 29.67x NTM earnings and a 34.17% premium to fundamental fair value ($203.99). The risk-reward asymmetry is heavily negative, with DCF-derived values of $139.15 indicating deep valuation vulnerability if margin milestones stumble.4
An annualized dividend payout of $2.92 per share yields roughly 1.07%, offering negligible downside defense against an implied equity return of -25.47% toward fair value.4
Even after upward FY2027 estimate revisions, the stock's forward P/E multiple is elevated at 29.67x versus peers LIN (24.51x) and APD (19.23x). Any operational friction will cause rapid multiple contraction without growth acceleration.3
We recommend a Sell rating on Ecolab Inc.4
Ecolab trades at 29.67x forward P/E, a 10.4-multiple premium over peer APD (19.23x). Any industrial manufacturing deceleration or commodity inflation risks margin compression and sharp multiple de-rating toward fundamental cash flow models ($139.15 to $180.24). Investors should sell into current strength.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Consolidated FY2025 EBIT margin was 17.02% ($2,737.6M EBIT on $16,081.2M revenue). Management indicated expectations of high-single-digit raw material commodity inflation for the balance of the year alongside a 60 bps gross margin drag from Ovivo. If customer resistance prevents rapid value pricing recovery and operating margin falls below 16.5%, earnings power faces a -24.0% fair value impact.57
Ecolab trades at a forward P/E multiple of 29.67x, representing an expansive premium over peer Air Products & Chemicals at 19.23x and peer median levels of 21.38x. Any growth stumble or failure to reach guided 20% operating margins by 2027 risks compressing the valuation multiple toward 21.4x, triggering a -21.5% fair value decline.345
Inability to pass through high-single-digit raw material commodity inflation or customer resistance to value pricing structures.
현재:44.51% in FY2025 ($7,158.1M gross profit on $16,081.2M revenue)
다음이면 경고Consolidated gross margin below 42.0%
Operating leverage erosion caused by severe input cost inflation and integration drag from acquired entities such as Ovivo (60 bps drag).
다음이면 경고Operating income margin below 16.5%
Ramp execution friction or biopharma demand soft patches failing to absorb new China purification plant capacity.
현재:$706.1M in FY2025 (4.39% of revenue)
다음이면 경고Healthcare and Life Sciences segment revenue growth below 5.0% YoY
Multiple de-rating toward peer median triggered by decelerating organic volume growth or missed operating margin targets.
현재:29.67x forward P/E vs peer APD at 19.23x and LIN at 24.51x
다음이면 경고Forward P/E compressing below 21.4x peer median
| medium |
| 12-24 months |
| Increasing penetration of higher-margin digital monitoring platforms (Ecolab Digital targeting >20% growth) and expansion in data center liquid cooling.5 |
| Integration drag and margin dilution from major M&A transactions, including the 60 bps gross margin drag from Ovivo and ROIC dilution from CoolIT. | medium | 12-36 months | Disciplined capital allocation prioritizing debt reduction from operating cash flows ($2,952.6M in FY2025) and bolt-on synergy extraction.7 |
Under the moderate discount rate, US$35.39 comes from forecast-period earnings and US$143 from the long-term value, totaling US$179.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows (US$37.29) plus discounted terminal value (US$133) minus signed per current share (US$31.33) equals the US$139 lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Rapid commercial scaling of CoolIT liquid cooling systems across AI data centers multiplies addressable sales opportunities 3x to 5x, while China purification debottlenecking sustains double-digit life sciences growth toward a 30% ROI. Value pricing overcomes raw material inflation rapidly within three months, accelerating operating margin expansion beyond 20% and driving valuation toward the upper fair value boundary of $251.65.5
As Ecolab's largest segment, volume deceleration below guided expectations would falsify core cash flow durability.
Debottlenecking purification capacity is critical to sustaining life sciences growth and reaching a 30% segment margin at scale.5
Failure to pass through input cost inflation promptly will compress gross margins below targeted operating thresholds.
| $20.60B |
| $21.84B |
| $23.04B |
| Revenue growth | 11.5% | 7.9% | 6.5% | 6.0% | 5.5% |
| Operating margin | 18.0% | 19.5% | 20.0% | 20.0% | 20.0% |
| Operating income | $3.23B | $3.77B | $4.12B | $4.37B | $4.61B |
| Tax rate | 18.3% | 18.3% | 18.3% | 18.3% | 18.3% |
| NOPAT | $2.64B | $3.08B | $3.37B | $3.57B | $3.77B |
| Reinvestment | $527.31M | $616.61M | $606.18M | $571.15M | $564.91M |
| Reinvestment rate (of NOPAT) | 20.0% | 20.0% | 18.0% | 16.0% | 15.0% |
| Free cash flow to firm | $2.11B | $2.47B | $2.76B | $3.00B | $3.20B |
| Water Services revenue | $8.56B | $9.24B | $9.84B | $10.43B | $11.01B |
| Global Institutional revenue | $6.64B | $7.17B | $7.64B | $8.10B | $8.54B |
| Global Pest Elimination revenue | $1.36B | $1.47B | $1.56B | $1.66B | $1.75B |
| Global Healthcare and Life Sciences revenue | $786.87M | $849.35M | $904.55M | $958.83M | $1.01B |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Ecolab maintains a balanced capital allocation strategy prioritizing internal growth capex, disciplined bolt-on M&A, and shareholder capital return. In FY2025, capex was $1,048.3M alongside $672.6M of D&A, funding plant capacity additions in China and IoT sensor rollouts. Strategic acquisitions including CoolIT and Ovivo expand addressable high-tech capabilities, though Scott Kirkland noted that major transactions cause near-term ROIC dilution before recovering by 2028. Total debt of $9,429.3M results in net debt of $8,783.1M, which requires consistent operating cash flow generation ($2,952.6M in FY2025) in an elevated interest rate environment where pre-tax debt costs stand at 5.78%.
Operating margin was 17.02% in FY2025, while management affirmed a 19% target for 2H 2026 and 20% in 2027.
Earnings growth in 2026-2027 is heavily reliant on margin expansion rather than volume growth alone, exposing results to operational execution risk.
Total debt of $9,429.3M creates net debt of $8,783.1M against $2,737.6M of EBIT.
While manageable, financial leverage limits aggressive share repurchases and increases earnings sensitivity to higher refinancing rates.
| 마진 |
|---|
| ECL | Ecolab Inc. | $76.7B | 29.7x | 4.6x | 20.7x | 22.0% | — |
| SHW | The Sherwin-Williams Company | $77.6B | 23.5x | 3.2x | 19.5x | 65.1% | 18.1% |
| APD | Air Products and Chemicals Inc. | $61.8B | 19.2x | 4.9x | 17.6x | 0.0% | 25.5% |
| LIN | Linde plc | $221.0B | 24.5x | 6.2x | 17.8x | 18.4% | 28.1% |
| FCX | Freeport-McMoRan Inc. | $103.5B | 17.2x | 4.0x | 12.8x | 14.8% | 33.4% |
| negative |
| Persistent raw material commodity inflation, which management notes at high-single-digit levels, elevates working capital and challenges gross profit conversion during periods of delayed price adjustment. |
| Healthcare and Life Sciences revenue growth | Below 5.0% YoY | Demote bioprocessing and high-tech revenue contribution schedules. |
| Annual Free Cash Flow generation | Below $1,750M (down from $1,904.3M in FY2025) | Re-assess net leverage burden ($8,783.1M net debt) in elevated interest rate conditions. |
